Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. (Q36664245)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Timothy P Cripe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Jennifer L Leddon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Chun-Yu Chen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Mark A Currier

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Pin-Yi Wang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Francesca A Jung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Nicholas L Denton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Kevin M Cripe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Amy C Gross

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Timothy D Eubank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

William F Goins

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Joseph C Glorioso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

David A Hildeman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Paola Grandi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

21 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

Molecular therapy oncolytics

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

14010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy

3 April 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Childhood and adolescent cancer statistics, 2014.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Rhabdomyosarcomas: an overview on the experimental animal models.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Virotherapy induces massive infiltration of neutrophils in a subset of tumors defined by a strong endogenous interferon response activity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Murine rhabdomyosarcoma is immunogenic and responsive to T‐cell‐based immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Oncolytic virotherapy reaches adolescence

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Outcomes for children and adolescents with cancer: challenges for the twenty-first century

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Oncolytic herpes simplex virus vectors for cancer virotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Engineering HSV-1 vectors for gene therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Amgen announces oncolytic virus shrinks tumors

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4782947

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

20 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27119100

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Oncolytics Biotech releases REOLYSIN phase I clinical trial results

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27119100

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/MTO.2014.10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

27119100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27119100%20AND%20SRC:MED&resulttype=core&format=json